Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Estimating the dengue burden in India.

Wilder-Smith A, Rupali P.

Lancet Glob Health. 2019 Jun 11. pii: S2214-109X(19)30249-9. doi: 10.1016/S2214-109X(19)30249-9. [Epub ahead of print] No abstract available.

2.

Managing severe yellow fever in the intensive care: lessons learnt from Brazil.

Kallas EG, Wilder-Smith A.

J Travel Med. 2019 Jun 10. pii: taz043. doi: 10.1093/jtm/taz043. [Epub ahead of print] No abstract available.

PMID:
31180486
3.

Evaluation of intensified dengue control measures with interrupted time series analysis in the Panadura Medical Officer of Health division in Sri Lanka: a case study and cost-effectiveness analysis.

Liyanage P, Rocklöv J, Tissera H, Palihawadana P, Wilder-Smith A, Tozan Y.

Lancet Planet Health. 2019 May;3(5):e211-e218. doi: 10.1016/S2542-5196(19)30057-9.

4.

Improving clinical management of patients with severe yellow fever.

Wilder-Smith A, Chen LH, Melo A, Visser LG.

Lancet Infect Dis. 2019 May 16. pii: S1473-3099(19)30122-7. doi: 10.1016/S1473-3099(19)30122-7. [Epub ahead of print] No abstract available.

PMID:
31104910
5.

Application of a targeted-enrichment methodology for full-genome sequencing of Dengue 1-4, Chikungunya and Zika viruses directly from patient samples.

Kamaraj US, Tan JH, Xin Mei O, Pan L, Chawla T, Uehara A, Wang LF, Ooi EE, Gubler DJ, Tissera H, Ng LC, Wilder-Smith A, de Sessions PF, Barkham T, Anderson DE, Sessions OM.

PLoS Negl Trop Dis. 2019 Apr 25;13(4):e0007184. doi: 10.1371/journal.pntd.0007184. eCollection 2019 Apr.

6.

A Prospective Study on the Impact and Out-of-Pocket Costs of Dengue Illness in International Travelers.

Tozan Y, Headley TY, Sewe MO, Schwartz E, Shemesh T, Cramer JP, Eberhardt KA, Ramharter M, Harrison N, Leder K, Angheben A, Hatz C, Neumayr A, Chen LH, De Pijper CA, Grobusch MP, Wilder-Smith A.

Am J Trop Med Hyg. 2019 Jun;100(6):1525-1533. doi: 10.4269/ajtmh.18-0780.

PMID:
30994088
7.

Yellow fever: is Asia prepared for an epidemic?

Wilder-Smith A, Lee V, Gubler DJ.

Lancet Infect Dis. 2019 Mar;19(3):241-242. doi: 10.1016/S1473-3099(19)30050-7. No abstract available.

PMID:
30833057
8.

Dengue.

Wilder-Smith A, Ooi EE, Horstick O, Wills B.

Lancet. 2019 Jan 26;393(10169):350-363. doi: 10.1016/S0140-6736(18)32560-1. Review.

PMID:
30696575
9.

Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews.

Luo R, Fongwen N, Kelly-Cirino C, Harris E, Wilder-Smith A, Peeling RW.

Clin Microbiol Infect. 2019 Jun;25(6):659-666. doi: 10.1016/j.cmi.2019.01.002. Epub 2019 Jan 18. Review.

10.

Influenza on cruise ships.

Young BE, Wilder-Smith A.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay146. No abstract available.

PMID:
30649459
11.

Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates.

Vannice KS, Cassetti MC, Eisinger RW, Hombach J, Knezevic I, Marston HD, Wilder-Smith A, Cavaleri M, Krause PR.

Vaccine. 2019 Feb 4;37(6):863-868. doi: 10.1016/j.vaccine.2018.12.040. Epub 2019 Jan 11.

12.

Can dengue virus be sexually transmitted?

Wilder-Smith A.

J Travel Med. 2019 May 10;26(3). pii: tay157. doi: 10.1093/jtm/tay157. No abstract available.

PMID:
30590715
13.

Novel tools for the surveillance and control of dengue: findings by the DengueTools research consortium.

Wilder-Smith A, Tissera H, AbuBakar S, Kittayapong P, Logan J, Neumayr A, Rocklöv J, Byass P, Louis VR, Tozan Y, Massad E, Preet R.

Glob Health Action. 2018;11(1):1549930. doi: 10.1080/16549716.2018.1549930.

14.

Clinical Pearls in travellers and migrants.

Wilder-Smith A, van Genderen PJ, Barkati S, Coyle C, Staehelin C, Richter J, Bottieau E.

J Travel Med. 2019 Jan 1;26(1). doi: 10.1093/jtm/tay147. No abstract available.

PMID:
30535197
15.

Sentinel Surveillance in Travel Medicine: 20 Years of GeoSentinel Publications (1999-2018).

Wilder-Smith A, Boggild AK.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay139. No abstract available.

PMID:
30508133
16.

Risk of severe dengue is higher in patients with sickle cell disease: a scoping review.

Wilder-Smith A, Leong WY.

J Travel Med. 2019 Jan 1;26(1). doi: 10.1093/jtm/tay136. No abstract available.

PMID:
30476342
17.

Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology.

Jaenisch T, Hendrickx K, Erpicum M, Agulto L, Tomashek KM, Dempsey W, Siqueira JB, Marks MA, Fay MP, Laughlin C, L'Azou M, Leo YS, Narvaez F, Teyssou R, Thomas SJ, Tissera H, Wallace D, Wilder-Smith A, Gubler DJ, Cassetti MC.

BMC Med Res Methodol. 2018 Nov 15;18(1):134. doi: 10.1186/s12874-018-0601-z.

18.

Hell's itch due to sunburn.

Wilder-Smith AJ.

J Travel Med. 2019 Jan 1;26(1). doi: 10.1093/jtm/tay124. No abstract available.

PMID:
30423157
19.

Risk of Dengue in Travelers: Implications for Dengue Vaccination.

Wilder-Smith A.

Curr Infect Dis Rep. 2018 Oct 29;20(12):50. doi: 10.1007/s11908-018-0656-3. Review.

20.

Reply to 'Timing of administration of dengue vaccine in travellers with a recent confirmed dengue infection'.

Wilder-Smith A.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay105. No abstract available.

PMID:
30346578
21.

Projecting the end of the Zika virus epidemic in Latin America: a modelling analysis.

O'Reilly KM, Lowe R, Edmunds WJ, Mayaud P, Kucharski A, Eggo RM, Funk S, Bhatia D, Khan K, Kraemer MUG, Wilder-Smith A, Rodrigues LC, Brasil P, Massad E, Jaenisch T, Cauchemez S, Brady OJ, Yakob L.

BMC Med. 2018 Oct 3;16(1):180. doi: 10.1186/s12916-018-1158-8.

22.

Semiannual Versus Annual Influenza Vaccination in Older Adults in the Tropics: An Observer-blind, Active-comparator-controlled, Randomized Superiority Trial.

Young B, Sadarangani S, Haur SY, Yung CF, Barr I, Connolly J, Chen M, Wilder-Smith A.

Clin Infect Dis. 2019 Jun 18;69(1):121-129. doi: 10.1093/cid/ciy836.

PMID:
30277500
23.

Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.

Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, Barrett A, Ferdinand E, Flasche S, Guzman M, Novaes HM, Ng LC, Smith PG, Tharmaphornpilas P, Yoon IK, Cravioto A, Farrar J, Nolan TM.

Lancet Infect Dis. 2019 Jan;19(1):e31-e38. doi: 10.1016/S1473-3099(18)30494-8. Epub 2018 Sep 5. Review.

PMID:
30195995
24.

Estimating the size of Aedes aegypti populations from dengue incidence data: Implications for the risk of yellow fever outbreaks.

Massad E, Amaku M, Coutinho FAB, Struchiner CJ, Lopez LF, Wilder-Smith A, Burattini MN.

Infect Dis Model. 2017 Dec 8;2(4):441-454. doi: 10.1016/j.idm.2017.12.001. eCollection 2017 Nov.

25.

Zika in travellers 1947-2017: a systematic review.

Wilder-Smith A, Chang CR, Leong WY.

J Travel Med. 2018 Jul 1;25(1). doi: 10.1093/jtm/tay044.

PMID:
30016469
26.

Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers.

Wilder-Smith A.

J Travel Med. 2018 Aug 1;25(1). doi: 10.1093/jtm/tay057. No abstract available.

PMID:
30016457
27.

Fractional-Dose Yellow Fever Vaccination - Advancing the Evidence Base.

Vannice K, Wilder-Smith A, Hombach J.

N Engl J Med. 2018 Aug 16;379(7):603-605. doi: 10.1056/NEJMp1803433. Epub 2018 Jul 11. No abstract available.

28.

Dengue vaccine: reliably determining previous exposure.

Ariën KK, Wilder-Smith A.

Lancet Glob Health. 2018 Aug;6(8):e830-e831. doi: 10.1016/S2214-109X(18)30295-X. Epub 2018 Jun 22. No abstract available.

29.

Zika vaccines and therapeutics: landscape analysis and challenges ahead.

Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I, Simmons CP.

BMC Med. 2018 Jun 6;16(1):84. doi: 10.1186/s12916-018-1067-x.

30.

The risk of urban yellow fever resurgence in Aedes-infested American cities.

Massad E, Amaku M, Coutinho FAB, Struchiner CJ, Lopez LF, Coelho G, Wilder-Smith A, Burattini MN.

Epidemiol Infect. 2018 Jul;146(10):1219-1225. doi: 10.1017/S0950268818001334. Epub 2018 May 30.

31.

Leptospirosis among Returned Travelers: A GeoSentinel Site Survey and Multicenter Analysis-1997-2016.

de Vries SG, Visser BJ, Stoney RJ, Wagenaar JFP, Bottieau E, Chen LH, Wilder-Smith A, Wilson M, Rapp C, Leder K, Caumes E, Schwartz E, Hynes NA, Goorhuis A, Esposito DH, Hamer DH, Grobusch MP, For The GeoSentinel Surveillance Network.

Am J Trop Med Hyg. 2018 Jul;99(1):127-135. doi: 10.4269/ajtmh.18-0020. Epub 2018 May 10.

PMID:
29761761
32.

Asymptomatic Prenatal Zika Virus Infection and Congenital Zika Syndrome.

Paixao ES, Leong WY, Rodrigues LC, Wilder-Smith A.

Open Forum Infect Dis. 2018 Apr 7;5(4):ofy073. doi: 10.1093/ofid/ofy073. eCollection 2018 Apr.

33.

Dengue virus not detected in human semen.

Molton JS, Low I, Choy MMJ, Aw PPK, Hibberd ML, Tambyah PA, Wilder-Smith A.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay023.

PMID:
29672710
34.

Estimating the number of unvaccinated Chinese workers against yellow fever in Angola.

Wilder-Smith A, Massad E.

BMC Infect Dis. 2018 Apr 17;18(1):185. doi: 10.1186/s12879-018-3084-y.

35.

Zika virus infection in the returning traveller: what every neurologist should know.

Leonhard SE, Lant S, Jacobs BC, Wilder-Smith A, Ferreira MLB, Solomon T, Willison HJ.

Pract Neurol. 2018 Aug;18(4):271-277. doi: 10.1136/practneurol-2017-001789. Epub 2018 Apr 4. Review.

36.

Four-year safety follow-up of the tetravalent dengue vaccine CYD-TDV.

Wilder-Smith A.

Clin Microbiol Infect. 2018 Jul;24(7):680-681. doi: 10.1016/j.cmi.2018.03.024. Epub 2018 Mar 23. No abstract available.

PMID:
29581052
37.

Estimating the probability of dengue virus introduction and secondary autochthonous cases in Europe.

Massad E, Amaku M, Coutinho FAB, Struchiner CJ, Burattini MN, Khan K, Liu-Helmersson J, Rocklöv J, Kraemer MUG, Wilder-Smith A.

Sci Rep. 2018 Mar 15;8(1):4629. doi: 10.1038/s41598-018-22590-5.

38.

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J.

Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7.

39.

Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report.

Goncalves A, Peeling RW, Chu MC, Gubler DJ, de Silva AM, Harris E, Murtagh M, Chua A, Rodriguez W, Kelly C, Wilder-Smith A.

J Infect Dis. 2018 Mar 13;217(7):1060-1068. doi: 10.1093/infdis/jix678.

40.

ZikaPLAN: Zika Preparedness Latin American Network.

Wilder-Smith A, Preet R, Renhorn KE, Ximenes RA, Rodrigues LC, Solomon T, Neyts J, Lambrechts L, Willison H, Peeling R, Falconar AK, Precioso AR, Logan J, Lang T, Endtz HP, Erasmus MC, Massad E.

Glob Health Action. 2017;10(1):1398485. doi: 10.1080/16549716.2017.1398485.

41.

Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies.

Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen MI.

J Infect Dis. 2018 Feb 14;217(5):731-741. doi: 10.1093/infdis/jix632.

PMID:
29220496
42.

Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients.

Tissera H, Rathore APS, Leong WY, Pike BL, Warkentien TE, Farouk FS, Syenina A, Eong Ooi E, Gubler DJ, Wilder-Smith A, St John AL.

J Infect Dis. 2017 Nov 27;216(9):1112-1121. doi: 10.1093/infdis/jix447.

43.

Household costs of hospitalized dengue illness in semi-rural Thailand.

Tozan Y, Ratanawong P, Sewe MO, Wilder-Smith A, Kittayapong P.

PLoS Negl Trop Dis. 2017 Sep 22;11(9):e0005961. doi: 10.1371/journal.pntd.0005961. eCollection 2017 Sep.

44.

Yellow fever vaccination: estimating coverage.

Wilder-Smith A.

Lancet Infect Dis. 2017 Nov;17(11):1109-1111. doi: 10.1016/S1473-3099(17)30494-2. Epub 2017 Aug 16. No abstract available.

45.

The public health value of vaccines beyond efficacy: methods, measures and outcomes.

Wilder-Smith A, Longini I, Zuber PL, Bärnighausen T, Edmunds WJ, Dean N, Spicher VM, Benissa MR, Gessner BD.

BMC Med. 2017 Jul 26;15(1):138. doi: 10.1186/s12916-017-0911-8.

46.

Analysis of Dengue Serotype 4 in Sri Lanka during the 2012-2013 Dengue Epidemic.

Uehara A, Tissera HA, Bodinayake CK, Amarasinghe A, Nagahawatte A, Tillekeratne LG, Cui J, Reller ME, Palihawadana P, Gunasena S, Desilva AD, Wilder-Smith A, Gubler DJ, Woods CW, Sessions OM.

Am J Trop Med Hyg. 2017 Jul;97(1):130-136. doi: 10.4269/ajtmh.16-0540.

47.

On the origin and timing of Zika virus introduction in Brazil.

Massad E, Burattini MN, Khan K, Struchiner CJ, Coutinho FAB, Wilder-Smith A.

Epidemiol Infect. 2017 Aug;145(11):2303-2312. doi: 10.1017/S0950268817001200. Epub 2017 Jun 15.

PMID:
28675351
48.

Utilization of HIV testing services among pregnant mothers in low income primary care settings in northern Ethiopia: a cross sectional study.

Alemu YM, Ambaw F, Wilder-Smith A.

BMC Pregnancy Childbirth. 2017 Jun 24;17(1):199. doi: 10.1186/s12884-017-1389-2.

49.

Zika virus tropism and interactions in myelinating neural cell cultures: CNS cells and myelin are preferentially affected.

Cumberworth SL, Barrie JA, Cunningham ME, de Figueiredo DPG, Schultz V, Wilder-Smith AJ, Brennan B, Pena LJ, Freitas de Oliveira França R, Linington C, Barnett SC, Willison HJ, Kohl A, Edgar JM.

Acta Neuropathol Commun. 2017 Jun 23;5(1):50. doi: 10.1186/s40478-017-0450-8.

50.

An update on Zika vaccine developments.

Durbin A, Wilder-Smith A.

Expert Rev Vaccines. 2017 Aug;16(8):781-787. doi: 10.1080/14760584.2017.1345309. Review.

PMID:
28633549

Supplemental Content

Loading ...
Support Center